97s色视频一区二区三区在线-97爱爱爱-97爱色-97超级碰久久久久香蕉人人-97超级碰碰碰碰久久久久-97超级碰碰人妻中文字幕

Molecular immunology department

Molecular immunology department owns everal technology platforms including ELISA/ELISpot, reverse dot blot, and time- resolved fluorescence. The product lines developed can be used for TB infection screening, diagnosis and detection of drug resistance. Among them is the tuberculosis T cell immune detection kit with independent intellectual property (patented in China), which has won CFDA clinical approval and production license; the in- development kit for rapid diagnosis of tuberculosis drug sensitivity based on reverse dot blot will help to achieve an all- round and rapid detection of MDR- TB; the in- development tuberculosis molecular diagnostic kit is simple to use and does not require any special equipment, suitable for the needs of tuberculosis prevention and control at all levels of disease control facilities.
    Molecular immunology department has taken part in the major projects of the 12th five- year plan and has established a long- term cooperation with Institute of Microbiology of Chinese Academy of Sciences, Peking University, Tsinghua University, Chinese Center for Disease Control and Prevention and Beijing Chest Hospital. The platform established for the conversion of biological reagents ensures sustained innovation of the product lines.

分子診斷部

分子診斷部以microRNA為切入點(diǎn)，專注于重大癌癥、艾滋病、結(jié)核病、肝病等microRNA診斷試劑盒的研制，并提供從microRNA表達(dá)譜檢測到功能研究的全套技術(shù)服務(wù)。本平臺采用自主知識產(chǎn)權(quán)發(fā)明專利"三步法qPCR"技術(shù)和獨(dú)特的外源RNA對照設(shè)計(jì)，實(shí)現(xiàn)血清、血漿、組織、細(xì)胞、石蠟組織切片中microRNA表達(dá)量的檢測。

艾滋病快速進(jìn)展microRNA標(biāo)志物已申報(bào)獲得5項(xiàng)國家發(fā)明專利，乳腺癌特異性microRNA標(biāo)志物已申報(bào)獲得4項(xiàng)國家發(fā)明專利，乙肝、肝硬化特異性microRNA標(biāo)志物已申報(bào)3項(xiàng)國家發(fā)明專利，肝硬化miRNA診斷試劑盒已啟動注冊申報(bào)程序。